Ann: COVID-19 Study Recruits Multiple Patients in Europe, page-2

MELBOURNE, Australia, 23 April 2021: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, advises that the first 24 patients have been recruited into the feasibility/Phase 3 ACE2 renin angiotensin system (RAS) modulation study domain in patients with COVID-19 pneumonia, which incorporates DMX-200. Of those 24 subjects enrolled, 22 were in the Netherlands (UMC Utrecht) and 2 where in the UK (Southampton & Edinburgh). According to the World Health Organisation (WHO), 5.2 million new cases of COVID-19 were reported in the last seven days, the most cases reported in a week since the beginning of the pandemic. 300,000 of these cases were reported in one day in India alone, where DMX-200 is also being trialled in COVID-19 patients. The number of cases worldwide has been increasing for eight consecutive weeks, and the number of deaths has been on the rise for the past five weeks. Despite the introduction of vaccines, the aim to reduce the symptoms caused by COVID-19 and improve treatments for hospitalised patients remains crucial. ACE2 RAS modulation domain design The feasibility/Phase 3 study is a multi-centre, randomised, standard of care vs multi-active comparators platform study in patients with COVID-19. The study domain protocol can be seen at https://www.remapcap.org/protocol-documents. In the REMAP-CAP approved ACE2 RAS study domain, participants who meet platform entry criteria will be randomised to receive one RAS blockade strategies or a control: • ARB in combination with DMX-200 • Angiotensin receptor blocker (ARB) • Angiotensin converting enzyme (ACE) inhibitor • No RAS inhibitor (no placebo) The overarching REMAP-CAP study incorporating DMX-200 is funded by the European Union through the H2020 Project called “Rapid European COVID-19 Emergency Research response,” which uses the acronym “RECOVER”. The RECOVER project is among the first 18 projects that the